Sarepta price target raised to $167 from $164 at UBS

UBS raised the firm’s price target on Sarepta to $167 from $164 and keeps a Buy rating on the shares. Sarepta’s Q4 print was “fairly pedestrian,” and nothing was said on the call that was incrementally negative with regard to the likely label outcome and in fact, we see the potential for a full ambulatory indication as increasingly likely, in part driven by recent commentary from Peter Marks at various public speaking engagements, the analyst tells investors in a research note.